Copenhagen, 2014-01-02 16:15 CET (GLOBE NEWSWIRE) --  

ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF) today announced that the Company will present at the Biotech Showcase™ 2014 Conference being held at the Parc 55 Wyndham San Francisco Union Square Hotel in San Francisco, CA. Jens Bager, President and CEO, will provide an overview of the Company and its key programmes on Wednesday, 15 January 2014 at 3:30 PM Pacific Time (11:30 Pm GMT) in the Mission II Room. 

If you are interested in meeting with ALK’s management the week of January 13 in San Francisco, please contact Janet Dally on +1 609 466 0466, mobile +1 732 319 2833 or e-mail: janetdally@maidstonelifesci.com

ALK-Abelló A/S
 

Jens Bager
President and CEO 

For further information please contact:
Jens Bager, President and CEO, tel. +45 4574 7576

Investor Relations:  
Per Plotnikof, tel. +45 4574 7527, mobile +45 2261 2525

Janet Dally, tel. +1 609 466 0466, mobile +1 732 319 2833, e-mail: janetdally@maidstonelifesci.com

Press:
Martin Barlebo, tel. +45 4574 7901, mobile +45 2064 1143

About ALK
ALK is a research-driven global pharmaceutical company focusing on allergy prevention, diagnosis and treatment. ALK is the world leader in allergy immunotherapy – a unique treatment of the underlying cause of allergy. The company has approximately 1,800 employees with subsidiaries, production facilities and distributors worldwide. ALK has entered into partnership agreements with Merck and Torii to commercialise allergy immunotherapy tablets in North America and Japan, respectively. The company is headquartered in Hørsholm, Denmark, and listed on NASDAQ OMX Copenhagen. Find more information at www.alk.net.